Edwards Lifesciences Company Insiders
| EW Stock | USD 88.61 0.86 0.98% |
Edwards Lifesciences' insiders are aggressively selling. The analysis of insiders' sentiment of trading Edwards Lifesciences Corp stock suggests that vertually all insiders are panicking at this time. Edwards Lifesciences employs about 19.8 K people. The company is managed by 33 executives with a total tenure of roughly 227 years, averaging almost 6.0 years of service per executive, having 600.0 employees per reported executive.
| Michael Mussallem Chairman Chairman of the Board, Chief Executive Officer |
| Larry Wood President Corporate Vice President - Transcatheter Aortic Valve Replacement |
Edwards Lifesciences' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-08 | Jean-Luc M Lemercier | Disposed 14400 @ 92.32 | View | ||
| 2024-04-04 | Michael A Mussallem | Disposed 29350 @ 92.42 | View | ||
| 2024-04-01 | Scott B Ullem | Disposed 7255 @ 94.89 | View | ||
| 2024-03-13 | Donald E Bobo Jr | Disposed 14500 @ 91.01 | View | ||
| 2024-03-11 | Jean-Luc M Lemercier | Disposed 14400 @ 91.68 | View | ||
| 2024-03-07 | Daniel J Lippis | Disposed 1715 @ 90.98 | View | ||
| 2024-03-04 | Michael A Mussallem | Disposed 29350 @ 86.67 | View | ||
| 2024-02-29 | Scott B Ullem | Disposed 7255 @ 85.59 | View | ||
| 2024-02-23 | Kieran Gallahue | Disposed 3058 @ 87.61 | View | ||
| 2024-02-21 | Daveen Chopra | Disposed 8200 @ 86.74 | View | ||
| 2024-02-15 | Catherine M Szyman | Disposed 27000 @ 85.62 | View | ||
| 2024-02-13 | Donald E Bobo Jr | Disposed 11000 @ 85.83 | View | ||
| 2024-02-12 | Robert W.A. Sellers | Disposed 12210 @ 87 | View | ||
| 2024-02-08 | Heisz Leslie Stone | Disposed 7056 @ 86.45 | View | ||
| 2024-02-01 | Scott B Ullem | Disposed 7255 @ 78.29 | View | ||
| 2024-01-12 | Donald E Bobo Jr | Disposed 10000 @ 75.67 | View | ||
| 2024-01-05 | Michael A Mussallem | Disposed 29350 @ 72.98 | View | ||
| 2023-12-29 | Scott B Ullem | Disposed 14510 @ 76.55 | View | ||
| 2023-12-15 | Daveen Chopra | Disposed 7000 @ 78.25 | View | ||
| 2023-12-13 | Donald E Bobo Jr | Disposed 8000 @ 71.86 | View |
Monitoring Edwards Lifesciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Edwards |
Edwards Lifesciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Edwards Lifesciences' future performance. Based on our forecasts, it is anticipated that Edwards will maintain a workforce of slightly above 19800 employees by May 2024.Edwards Lifesciences' latest congressional trading
Congressional trading in companies like Edwards Lifesciences Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Edwards Lifesciences by those in governmental positions are based on the same information available to the general public.
| 2023-12-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2023-12-04 | Representative John Curtis | Acquired Under $15K | Verify | ||
| 2023-10-03 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2023-05-25 | Representative Zoe Lofgren | Acquired Under $15K | Verify | ||
| 2023-04-03 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-04-03 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
| 2023-03-06 | Representative Daniel Goldman | Acquired $15K to $50K | Verify | ||
| 2021-09-16 | Representative Katherine M. Clark | Acquired Under $15K | Verify | ||
| 2021-02-16 | Representative Peter Meijer | Acquired Under $15K | Verify |
Edwards Lifesciences Management Team Effectiveness
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024.Net Income Applicable To Common Shares is likely to climb to about 1.8 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 550.8 M in 2024.
Edwards Lifesciences Workforce Comparison
Edwards Lifesciences Corp is one of the top stocks in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 19,840. Edwards Lifesciences totals roughly 19,800 in number of employees claiming about 100% of equities under Health Care industry.
Edwards Lifesciences Profit Margins
The company has Net Profit Margin (PM) of 0.23 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.39 %, which signifies that for every $100 of sales, it has a net operating income of $0.39.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.54 | 0.7702 |
|
| |||||
| Net Profit Margin | 0.25 | 0.2335 |
|
| |||||
| Operating Profit Margin | 0.16 | 0.2555 |
|
| |||||
| Pretax Profit Margin | 0.14 | 0.2661 |
|
| |||||
| Return On Assets | 0.078 | 0.1498 |
|
| |||||
| Return On Equity | 0.11 | 0.2109 |
|
|
Edwards Lifesciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edwards Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edwards Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Edwards Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 0.2941 | 5 | 17 | 64,362 | 135,044 |
| 2024-03-01 | 0.413 | 19 | 46 | 252,111 | 474,288 |
| 2023-12-01 | 0.4103 | 16 | 39 | 550,482 | 729,275 |
| 2023-09-01 | 0.5128 | 20 | 39 | 248,399 | 394,014 |
| 2023-06-01 | 0.7439 | 61 | 82 | 1,046,458 | 726,907 |
| 2023-03-01 | 0.5667 | 17 | 30 | 267,127 | 370,832 |
| 2022-12-01 | 0.4286 | 15 | 35 | 170,520 | 284,040 |
| 2022-09-01 | 0.5714 | 16 | 28 | 228,208 | 255,721 |
| 2022-06-01 | 0.4952 | 52 | 105 | 601,043 | 1,009,756 |
| 2022-03-01 | 0.3529 | 18 | 51 | 282,669 | 556,786 |
| 2021-12-01 | 0.4468 | 21 | 47 | 280,681 | 481,362 |
| 2021-09-01 | 0.4595 | 17 | 37 | 273,081 | 478,506 |
| 2021-06-01 | 0.7647 | 65 | 85 | 1,305,092 | 1,102,655 |
| 2021-03-01 | 0.4681 | 22 | 47 | 549,212 | 904,181 |
| 2020-12-01 | 0.3654 | 19 | 52 | 598,389 | 997,804 |
| 2020-09-01 | 0.386 | 22 | 57 | 684,177 | 1,193,484 |
| 2020-06-01 | 0.6633 | 65 | 98 | 608,771 | 645,577 |
| 2020-03-01 | 0.35 | 21 | 60 | 192,980 | 328,363 |
| 2019-12-01 | 0.4423 | 23 | 52 | 248,683 | 407,946 |
| 2019-09-01 | 0.3026 | 23 | 76 | 281,522 | 442,627 |
| 2019-06-01 | 0.7821 | 61 | 78 | 40,479,656 | 346,531 |
| 2019-03-01 | 0.3333 | 17 | 51 | 155,582 | 316,586 |
| 2018-12-01 | 0.2373 | 14 | 59 | 153,259 | 374,109 |
| 2018-09-01 | 0.3542 | 17 | 48 | 277,841 | 506,116 |
| 2018-06-01 | 0.8125 | 65 | 80 | 640,271 | 645,213 |
| 2018-03-01 | 0.2745 | 14 | 51 | 189,808 | 400,059 |
| 2017-12-01 | 0.3704 | 10 | 27 | 172,314 | 350,460 |
| 2017-09-01 | 0.3333 | 9 | 27 | 177,520 | 360,610 |
| 2017-06-01 | 0.9375 | 60 | 64 | 743,933 | 755,181 |
| 2017-03-01 | 0.3478 | 8 | 23 | 230,460 | 454,626 |
| 2016-12-01 | 0.3514 | 13 | 37 | 263,892 | 511,798 |
| 2016-09-01 | 0.413 | 19 | 46 | 290,014 | 595,134 |
| 2016-06-01 | 1.0577 | 55 | 52 | 814,043 | 845,110 |
| 2016-03-01 | 0.3235 | 11 | 34 | 246,950 | 562,163 |
| 2015-12-01 | 0.425 | 17 | 40 | 201,825 | 402,426 |
| 2015-09-01 | 0.3226 | 10 | 31 | 137,300 | 274,600 |
| 2015-06-01 | 1.0392 | 53 | 51 | 449,522 | 350,140 |
| 2015-03-01 | 0.4839 | 15 | 31 | 179,301 | 305,213 |
| 2014-12-01 | 0.5128 | 20 | 39 | 280,945 | 540,865 |
| 2014-09-01 | 0.4615 | 18 | 39 | 428,773 | 855,242 |
| 2014-06-01 | 1.4444 | 39 | 27 | 638,878 | 374,114 |
| 2014-03-01 | 0.5625 | 18 | 32 | 283,394 | 276,456 |
| 2013-12-01 | 0.5 | 7 | 14 | 112,850 | 225,700 |
| 2013-09-01 | 0.4667 | 7 | 15 | 123,050 | 246,100 |
| 2013-06-01 | 1.0238 | 43 | 42 | 820,457 | 332,066 |
| 2013-03-01 | 0.4412 | 15 | 34 | 189,518 | 380,390 |
| 2012-12-01 | 0.3939 | 13 | 33 | 177,045 | 359,298 |
| 2012-09-01 | 0.3571 | 20 | 56 | 381,443 | 780,954 |
| 2012-06-01 | 0.6271 | 74 | 118 | 1,175,674 | 1,367,282 |
| 2012-03-01 | 0.3766 | 29 | 77 | 499,420 | 1,006,367 |
| 2011-12-01 | 0.4643 | 13 | 28 | 246,730 | 493,144 |
| 2011-09-01 | 0.3548 | 11 | 31 | 252,895 | 526,525 |
| 2011-06-01 | 0.7606 | 54 | 71 | 941,572 | 820,271 |
| 2011-03-01 | 0.4667 | 7 | 15 | 202,043 | 327,870 |
| 2010-12-01 | 0.6029 | 41 | 68 | 534,766 | 1,081,235 |
| 2010-09-01 | 0.5 | 3 | 6 | 35,750 | 73,830 |
| 2010-06-01 | 1.4545 | 32 | 22 | 502,439 | 83,996 |
| 2010-03-01 | 0.5 | 31 | 62 | 498,451 | 955,248 |
| 2009-12-01 | 0.4545 | 15 | 33 | 191,226 | 382,702 |
| 2009-09-01 | 0.5 | 7 | 14 | 127,472 | 254,944 |
| 2009-06-01 | 1.1707 | 48 | 41 | 835,302 | 558,496 |
| 2009-03-01 | 0.4348 | 10 | 23 | 159,250 | 325,100 |
| 2008-12-01 | 0.4348 | 10 | 23 | 100,250 | 200,900 |
| 2008-09-01 | 0.3182 | 7 | 22 | 150,350 | 335,008 |
| 2008-06-01 | 0.2992 | 38 | 127 | 545,912 | 226,703 |
| 2008-03-01 | 0.0288 | 3 | 104 | 42,000 | 90,800 |
| 2007-12-01 | 0.0594 | 6 | 101 | 67,250 | 134,500 |
| 2007-09-01 | 0.0458 | 7 | 153 | 119,710 | 239,420 |
| 2007-06-01 | 0.4343 | 43 | 99 | 674,432 | 188,445 |
| 2007-03-01 | 0.0331 | 12 | 362 | 221,863 | 449,771 |
| 2006-12-01 | 0.129 | 8 | 62 | 68,482 | 127,946 |
| 2006-09-01 | 0.1081 | 8 | 74 | 57,720 | 194,000 |
| 2006-06-01 | 1.1026 | 43 | 39 | 806,145 | 176,514 |
| 2006-03-01 | 0.8333 | 5 | 6 | 57,000 | 54,000 |
| 2005-12-01 | 0.4286 | 3 | 7 | 27,000 | 54,942 |
| 2005-09-01 | 0.1358 | 11 | 81 | 107,501 | 228,500 |
| 2005-06-01 | 5.6667 | 34 | 6 | 678,620 | 54,000 |
| 2005-03-01 | 0.0606 | 2 | 33 | 34,917 | 69,834 |
| 2004-12-01 | 0.1333 | 6 | 45 | 70,583 | 138,400 |
| 2004-06-01 | 2.0 | 12 | 6 | 47,552 | 41,000 |
| 2004-03-01 | 0.1563 | 10 | 64 | 203,990 | 467,310 |
| 2003-12-01 | 2.0 | 2 | 1 | 323.00 | 10,000 |
| 2003-06-01 | 0.5 | 2 | 4 | 398.00 | 31,500 |
Edwards Lifesciences Notable Stakeholders
An Edwards Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Edwards Lifesciences often face trade-offs trying to please all of them. Edwards Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Edwards Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Mussallem | Chairman of the Board, Chief Executive Officer | Profile | |
| Larry Wood | Corporate Vice President - Transcatheter Aortic Valve Replacement | Profile | |
| Catherine Szyman | Corporate Vice President - Critical Care | Profile | |
| Scott Ullem | Chief Financial Officer, Corporate Vice President | Profile | |
| Huimin Wang | Corporate Vice President - Japan, Asia and Pacific | Profile | |
| JeanLuc Lemercier | Corporate Vice President - EMEA (Europe, Middle East and Africa) | Profile | |
| Bernard Zovighian | Corporate Vice President -Surgical Heart Valve Therapy | Profile | |
| David Erickson | Vice President - Investor Relations | Profile | |
| Donald Bobo | Corporate Vice President - Strategy and Corporate Development | Profile | |
| Paul LaViolette | Independent Director | Profile | |
| John Cardis | Independent Director | Profile | |
| Wesley Schack | Presiding Independent Director | Profile | |
| Leslie Heisz | Independent Director | Profile | |
| Barbara McNeil | Independent Director | Profile | |
| Steven Loranger | Independent Director | Profile | |
| Kieran Gallahue | Independent Director | Profile | |
| Nicholas Valeriani | Independent Director | Profile | |
| Angela Fuente | Director Engineering | Profile | |
| Martha Marsh | Lead Independent Director | Profile | |
| William Link | Independent Director | Profile | |
| Ramona Sequeira | Independent Director | Profile | |
| Patrick Verguet | Corporate VP of EMEA, Canada and Latin America | Profile | |
| Arnold Pinkston | Corporate Counsel | Profile | |
| Heisz Stone | Independent Director | Profile | |
| Mark Wilterding | Vice Relations | Profile | |
| MD FACC | Corporate Officer | Profile | |
| Daveen Chopra | Corporate Vice President - Surgical Structural Heart | Profile | |
| Christine McCauley | Corporate Resources | Profile | |
| Gary Sorsher | Senior Compliance | Profile | |
| Daniel Lippis | Greater Japan | Profile | |
| Todd Brinton | Co Officer | Profile | |
| Dirksen Lehman | Corporate Affairs | Profile | |
| Finn Haley | Vice Development | Profile |
About Edwards Lifesciences Management Performance
The success or failure of an entity such as Edwards Lifesciences Corp often depends on how effective the management is. Edwards Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Edwards management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Edwards management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.18 | 0.1 | |
| Return On Capital Employed | 0.19 | 0.14 | |
| Return On Assets | 0.15 | 0.08 | |
| Return On Equity | 0.21 | 0.11 |
The data published in Edwards Lifesciences' official financial statements usually reflect Edwards Lifesciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Edwards Lifesciences Corp. For example, before you start analyzing numbers published by Edwards accountants, it's critical to develop an understanding of what Edwards Lifesciences' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Edwards Lifesciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edwards Lifesciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Edwards Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edwards Lifesciences Corp. Please utilize our Beneish M Score to check the likelihood of Edwards Lifesciences' management manipulating its earnings.
Edwards Lifesciences Workforce Analysis
Traditionally, organizations such as Edwards Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Edwards Lifesciences within its industry.Edwards Lifesciences Manpower Efficiency
Return on Edwards Lifesciences Manpower
| Revenue Per Employee | 303.3K | |
| Revenue Per Executive | 182M | |
| Net Income Per Employee | 70.7K | |
| Net Income Per Executive | 42.4M | |
| Working Capital Per Employee | 143.4K | |
| Working Capital Per Executive | 86.1M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.3 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.